S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Why Your IRA Could Crash on January 16th? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Why Your IRA Could Crash on January 16th? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Why Your IRA Could Crash on January 16th? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Why Your IRA Could Crash on January 16th? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
NASDAQ:INBX

Inhibrx - INBX News Today

$27.25
+0.16 (+0.59%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$26.85
$28.43
50-Day Range
$17.49
$33.33
52-Week Range
$7.67
$45.99
Volume
374,502 shs
Average Volume
488,636 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.50
Get Inhibrx News Delivered to You Automatically

Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter.



INBX Media Mentions By Week

INBX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

INBX
News Sentiment

0.00

0.46

Average
Medical
News Sentiment

INBX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

INBX Articles
This Week

2

1

INBX Articles
Average Week

SourceHeadline
marketbeat.com logoInsider Selling: Inhibrx, Inc. (NASDAQ:INBX) Insider Sells 40,000 Shares of Stock
marketbeat.com - December 7 at 6:46 PM
seekingalpha.com logoInhibrx's drug for rare bone cancer shows promise in ongoing phase 1 study
seekingalpha.com - November 16 at 6:22 PM
finance.yahoo.com logoInhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma
finance.yahoo.com - November 16 at 6:22 PM
finance.yahoo.com logoInhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate
finance.yahoo.com - November 16 at 6:22 PM
finance.yahoo.com logoInhibrx Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
finance.yahoo.com - November 9 at 9:44 AM
finance.yahoo.com logoInhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
finance.yahoo.com - November 8 at 8:29 AM
finance.yahoo.com logoInhibrx, Inc. (INBX) Reports Q3 Loss, Misses Revenue Estimates
finance.yahoo.com - November 8 at 8:29 AM
finance.yahoo.com logoInhibrx Announces Participation in Upcoming Scientific Conferences
finance.yahoo.com - October 20 at 5:15 PM
msn.com logo$40 Million Bet On Inhibrx? 3 Stocks Insiders Are Buying
msn.com - October 13 at 12:48 PM
finance.yahoo.com logoInvestors in Inhibrx (NASDAQ:INBX) have unfortunately lost 18% over the last year
finance.yahoo.com - October 13 at 7:34 AM
finance.yahoo.com logoInhibrx's Experimental Drug For Inherited Disease Capable For Accelerated FDA Approval, Shares Surge
finance.yahoo.com - October 12 at 9:10 AM
investorplace.com logoWhy Is Inhibrx (INBX) Stock Soaring 45% Today?
investorplace.com - October 4 at 5:02 PM
seekingalpha.com logoInhibrx stock soars 33% on potential accelerated approval path for INBRX-101 after FDA discussions
seekingalpha.com - October 4 at 4:40 PM
finance.yahoo.com logoInhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study
finance.yahoo.com - October 4 at 10:14 AM
finance.yahoo.com logoInhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency
finance.yahoo.com - October 3 at 6:23 PM
nasdaq.com logoIncreasing losses over year doesn't faze investors as stock advances 7.1% this past week
nasdaq.com - August 16 at 12:38 AM
finance.yahoo.com logoEuropean Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma
finance.yahoo.com - August 16 at 12:38 AM
finance.yahoo.com logoInhibrx, Inc. (INBX) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 9 at 1:54 AM
finance.yahoo.com logoInhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
finance.yahoo.com - August 8 at 8:53 PM
finance.yahoo.com logoInhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance
finance.yahoo.com - June 30 at 10:26 AM
seekingalpha.com logoInhibrx: Potential To Move To Registration Study With INBRX-101 (NASDAQ:INBX) - Seeking Alpha
seekingalpha.com - June 10 at 4:12 PM
finance.yahoo.com logoInhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting - Yahoo Finance
finance.yahoo.com - May 20 at 8:56 AM
finance.yahoo.com logoInhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting
finance.yahoo.com - May 19 at 5:54 PM
benzinga.com logoInhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder - Benzinga - Benzinga
benzinga.com - May 18 at 8:29 PM
streetinsider.com logoForm 8-K Inhibrx, Inc. For: May 16 - StreetInsider.com
streetinsider.com - May 18 at 3:29 PM
finance.yahoo.com logoMadrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences - Yahoo Finance
finance.yahoo.com - May 18 at 7:23 AM
finance.yahoo.com logoSteering committee of pulmonary and primary care experts aims to reduce time to diagnose complex lung diseases - Yahoo Finance
finance.yahoo.com - May 17 at 10:50 AM
benzinga.com logoInhibrx Reports Co.'s INBRX-101 Showed Favorable Safety Profile In Patients With Alpha-1 Antitrypsin Defi - Benzinga
benzinga.com - May 16 at 7:48 PM
finance.yahoo.com logoInhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder
finance.yahoo.com - May 16 at 7:48 PM
seekingalpha.com logoInhibrx stock falls despite INBRX-101 shows safety in early-stage study in genetic disease - Seeking Alpha
seekingalpha.com - May 16 at 2:13 PM
finance.yahoo.com logoINBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing
finance.yahoo.com - May 16 at 2:13 PM
nasdaq.com logoCara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
nasdaq.com - May 11 at 8:32 AM
finance.yahoo.com logoInhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
finance.yahoo.com - May 9 at 7:58 PM
finance.yahoo.com logoThe 17% return this week takes Inhibrx's (NASDAQ:INBX) shareholders one-year gains to 25%
finance.yahoo.com - May 5 at 8:36 AM
finance.yahoo.com logoInhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?
finance.yahoo.com - May 3 at 6:55 PM
finance.yahoo.com logoInhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting
finance.yahoo.com - April 5 at 6:38 PM
nasdaq.com logoInhibrx, Inc. Common Stock (INBX)
nasdaq.com - March 29 at 7:28 PM
finance.yahoo.com logoInhibrx Announces Details of Presentations at 2022 AACR Annual Meeting
finance.yahoo.com - March 24 at 7:45 PM
benzinga.com logoSMBC Nikko Initiates Coverage On Inhibrx with Outperform Rating, Announces Price Target of $40
benzinga.com - March 16 at 3:25 PM
seekingalpha.com logoInhibrx initiated as outperform at SMBC Nikko; sees 98% upside
seekingalpha.com - March 16 at 3:25 PM
marketwatch.com logoInhibrx Gets FDA Orphan Designation for INBRX-101 in AATD >INBX
marketwatch.com - March 3 at 3:03 PM
seekingalpha.com logoInhibrx's INBRX-101 for AAT deficiency gets FDA's orphan drug designation
seekingalpha.com - March 3 at 3:03 PM
finance.yahoo.com logoInhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
finance.yahoo.com - March 3 at 3:03 PM
nz.finance.yahoo.com logoInhibrx Selects Genialis ResponderID™ for Clinical Optimization Study of INBRX-109
nz.finance.yahoo.com - February 28 at 5:57 PM
finance.yahoo.com logoInhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights
finance.yahoo.com - February 28 at 5:55 PM
finance.yahoo.com logoInhibrx Announces Amended Loan Agreement with Oxford
finance.yahoo.com - February 22 at 6:09 PM
nasdaq.com logoInvestors one-year losses grow to 31% as the stock sheds US$100m this past week
nasdaq.com - February 14 at 1:50 PM
seekingalpha.com logoInhibrx falls after announcing resignation of medical chief
seekingalpha.com - January 25 at 10:42 AM
nasdaq.com logoRelative Strength Alert For Inhibrx
nasdaq.com - January 13 at 1:03 PM
benzinga.com logoInhibrx Announces Initial Phase 1 Dose Escalation Results For INBRX-106 In Combination With Keytruda Along With Updated Single Agent Data
benzinga.com - January 6 at 9:48 AM
markets.businessinsider.com logoInhibrx Shares Interim Data On INBRX-106 - Keytruda Combo Therapy In Solid Tumors
markets.businessinsider.com - January 5 at 8:28 AM
Get Inhibrx News Delivered to You Automatically

Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:INBX) was last updated on 12/8/2022 by MarketBeat.com Staff